Biosimilars in ophthalmology: “Is there a big change on the horizon?”

Retinal disease management has witnessed remarkable advances in posterior segment pharmacotherapy with the development of anti-VEGF molecules such as Lucentis(®) (ranibizumab), Eylea(®) (aflibercept), and off-label bevacizumab (Avastin). The US patents for ranibizumab and aflibercept will expire in...

Descripción completa

Detalles Bibliográficos
Autores principales: Sharma, Ashish, Reddy, Prahalad, Kuppermann, Baruch D, Bandello, Francesco, Lowenstein, Anat
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6207386/
https://www.ncbi.nlm.nih.gov/pubmed/30498330
http://dx.doi.org/10.2147/OPTH.S180393

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6207386/
https://www.ncbi.nlm.nih.gov/pubmed/30498330
http://dx.doi.org/10.2147/OPTH.S180393

Ejemplares similares